Stiripentol in Dravet syndrome: preventing prolonged seizures, reducing mortality, and improving value in care
- 1Universidade de São Paulo, Faculdade de Medicina, Departamento de Psiquiatria São Paulo SP Brazil.
- 2Universidade de São Paulo, Faculdade de Medicina, Centro Integrado de Doenças Genéticas e Raras São Paulo SP Brazil.
- 3Hospital de Pediatria Prof. Dr. Juan P Garrahan Buenos Aires BsAs Argentina.
Abstract
Dravet syndrome (DS) is a rare and severe developmental and epileptic encephalopathy that begins in infancy. Although nonconvulsive seizures may occur, the syndrome is marked by frequent, prolonged convulsive seizures followed by neurodevelopmental plateau, slowing, or regression. Stiripentol (STP) is an anti-seizure medication (ASM) approved for adjunctive use in DS in countries across Europe, North America, Asia, South America, Oceania, and Africa, though it is not yet approved in most countries in Latin America. The present narrative review summarizes current evidence on the clinical efficacy, safety, and cost-effectiveness of (STP). Data from randomized controlled trials, real-world studies, and systematic literature reviews demonstrate that (STP) reduces seizure frequency and duration, increases seizure-free intervals, and helps prevent or interrupt status epilepticus (SE). These effects are particularly relevant for lowering the risk of premature mortality and improving the quality of life (QoL) for patients and caregivers. Stiripentol has also shown a consistent safety profile, including in patients treated for over 18 years. Pharmacoeconomic analyses indicate that (STP) achieves meaningful seizure reduction and seizure freedom at a lower cost compared with cannabidiol and fenfluramine, which are ASMs also approved for the treatment of DS. Cost-utility models further support (STP)'s value under commonly accepted willingness-to-pay thresholds. Taken together, current evidence supports the role of (STP) as an effective, well-tolerated, and economically favorable treatment option for individuals with DS, including from early infancy.
Related
- Improving Hepatic Functional Reserve in Patients with Haemophilia and HIV/HCV-associated Cirrhosis: A Multicentre Prospective Study of Prolonged Foscenvivint Therapy
- Bridging the gap in maternal care: the role of community-based workers in preventing maternal mortality
- Iatrogenic Cushing Syndrome With Glucocorticoid-Induced Adrenal Insufficiency Following Prolonged Topical Clobetasol Use in an Adolescent
- Anesthetic Management of Stiff-Person Syndrome During Prolonged Lateral Skull Base Surgery: A Case Report and Phenotype-Informed Review
- Association Between the Naples Prognostic Score and In-Hospital Mortality in Patients with Type 2 Cardiorenal Syndrome: A Retrospective Cohort Study
BibTeX
@article{valente2026stiripentol,
title = {{Stiripentol in Dravet syndrome: preventing prolonged seizures, reducing mortality, and improving value in care}},
author = {Kette Valente and Roberto Caraballo},
journal = {Arquivos de Neuro-Psiquiatria},
year = {2026},
month = oct,
doi = {10.1055/s-0046-1829156},
url = {https://doi.org/10.1055/s-0046-1829156},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Stiripentol in Dravet syndrome: preventing prolonged seizures, reducing mortality, and improving value in care
AU - Kette Valente
AU - Roberto Caraballo
PY - 2026
DA - 2026/10/27
JO - Arquivos de Neuro-Psiquiatria
DO - 10.1055/s-0046-1829156
UR - https://doi.org/10.1055/s-0046-1829156
AB - Dravet syndrome (DS) is a rare and severe developmental and epileptic encephalopathy that begins in infancy. Although nonconvulsive seizures may occur, the syndrome is marked by frequent, prolonged convulsive seizures followed by neurodevelopmental plateau, slowing, or regression. Stiripentol (STP) is an anti-seizure medication (ASM) approved for adjunctive use in DS in countries across Europe, North America, Asia, South America, Oceania, and Africa, though it is not yet approved in most countries in Latin America. The present narrative review summarizes current evidence on the clinical efficacy, safety, and cost-effectiveness of (STP). Data from randomized controlled trials, real-world studies, and systematic literature reviews demonstrate that (STP) reduces seizure frequency and duration, increases seizure-free intervals, and helps prevent or interrupt status epilepticus (SE). These effects are particularly relevant for lowering the risk of premature mortality and improving the quality of life (QoL) for patients and caregivers. Stiripentol has also shown a consistent safety profile, including in patients treated for over 18 years. Pharmacoeconomic analyses indicate that (STP) achieves meaningful seizure reduction and seizure freedom at a lower cost compared with cannabidiol and fenfluramine, which are ASMs also approved for the treatment of DS. Cost-utility models further support (STP)'s value under commonly accepted willingness-to-pay thresholds. Taken together, current evidence supports the role of (STP) as an effective, well-tolerated, and economically favorable treatment option for individuals with DS, including from early infancy.
SN - 0004-282X
SN - 1678-4227
ER -